MedPath

To evaluate the Safety and efficacy of Unani medicine in the treatment of inflammation of the mouth and lips (stomatitis)

Phase 2
Recruiting
Conditions
Other forms of stomatitis, QulÄ (Stomatitis),
Registration Number
CTRI/2015/03/005633
Lead Sponsor
Central Council for Research in Unani Medicine CCRUM New Delhi
Brief Summary

This study is designed as a multicentric open trial in patients with **QulÄ‘ ( Stomatitis)****.**After screening, Patients will be enrolled if they satisfy inclusion and exclusion criteria. The patients will be assessed clinically on 3rd and 7th day of treatment. This includes subjective assessment of general well being and physical examination . The total duration of treatment will be one week. . Laboratory parameters for safety assessment will be conducted at baseline and end of study.

**Composition of PharmacopoeialFormulation ‘*****ZaroorKath*****’**

| | | | | |

| --- | --- | --- | --- | --- |

|**S. No.**

**Tibbi Name**

**Scientific Name**

**Parts used**

**Quantity**

|1

Zar-e- Ward

Rosa damascena Mill.

Pollen grains

1 part

|2

Kat Safed

Acacia catechu (Linn. f.) Willd.

Extract

-do-

|3

Dana Heel Khurd

Elettaria cardamomum (Linn.) Maton

Seeds

-do-

|4

Tabasheer

Bambusa arundinacea (Retz.) Roxb.

Siliceous secretion

-do-

|5

Kafoor

Cinnamomum camphora (Linn.) J. Presl

Extract

-do-

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
All
Target Recruitment
540
Inclusion Criteria

•Patients of either sex in the age group of 10-65 •Presence of single /multiple ulcers in the oral cavity and tongue With and without Presence of any of the following symptoms oDifficulty in eating/ chewing/Uneasiness in Speaking /Swallowing oBurning sensation / Pain in the mouth oExcessive salivation oCoated tongue.

Exclusion Criteria

•Disorders requiring long term treatment •Known cases of underlying systemic diseases such as crohn’s disease, ulcerative colitis, Celiac disease, lupus erythematosus, behcet’s disease, Cyclic neutropenia, immunodeficiency disorders •Known cases of carcinoma •Patients with hemoglobin level < 8 g /dl • Pregnant and lactating women.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement in signs and symptoms of Qulđ ( Stomatitis)7 days
Secondary Outcome Measures
NameTimeMethod
Haematological and biochemical assessment for safety assessment7 weeks

Trial Locations

Locations (7)

Clinical Research Unit (CRU), Karimganj

🇮🇳

Karimganj, ASSAM, India

Clinical Research Unit (CRU), Kurnool

🇮🇳

Kurnool, ANDHRA PRADESH, India

Regional Research Centre (RRC), Silchar

🇮🇳

Cachar, ASSAM, India

Regional Research Institute of Unani Medicine (RRIUM), Bhadrak

🇮🇳

Bhadrak, ORISSA, India

Regional Research Institute of Unani Medicine (RRIUM), Chennai

🇮🇳

Chennai, TAMIL NADU, India

Regional Research Institute of Unani Medicine (RRIUM), Mumbai

🇮🇳

Mumbai, MAHARASHTRA, India

Regional Research Institute of Unani Medicine (RRIUM), Patna

🇮🇳

Patna, BIHAR, India

Clinical Research Unit (CRU), Karimganj
🇮🇳Karimganj, ASSAM, India
DR WAHIDUZZAMAN
Principal investigator
03843267522
crukxj522@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.